Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance
- VernacularTitle:阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎患者的疗效观察
- Author:
Jiong YU
;
Zhaowen MA
;
Yu CHEN
;
Jianxin Lü
;
Hongcui CAO
;
Jifang SHENG
;
Lanjuan LI
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Drug resistance;
Adefovir dipivoxil
- From:
Chinese Journal of Clinical Infectious Diseases
2008;1(2):84-86
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treatment of chronic hepatitis B (CHB) patients with lamivudine (LAM) resistance. Methods There were treatment group (32 CHB patients with LAM resistance) and historical control group (24 CHB patients with LAM resistance) in this study. The treatment group received ADV 10 mg/d and LAM 100 mg/d for 48 weeks; the historical control group continued to use LAM monotherapy. During the treatment causes, serum HBV DNA levels, liver function and HBV serology were monitored regularly, and safety assessments were also conducted. Results In treatment group, mean HBV DNA levels decreased by 2.56 log10 eopies/ml and 2.93 log10 copies/ml, virus response rates were 50. 0% and 75.0%, ALT normalization rates were 53.1% and 68.8% after 24 and 48 weeks of treatment, respectively. The histological improvement rate was 65.6% after 48 weeks. Comparing with those in control group, the differences were statistically significant ( P <0. 05), while there was no significant statistical differences in HBeAg loss rate and HBeAg seroconversion rate between two groups. There was no severe adverse event during the treatment. Conclusion ADV is effective and safe in treatment of lamivudine-resistant CHB.
